Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $69.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 20.66% year-over-year to $69.9 million; the TTM figure through Mar 2026 stood at $69.9 million (down 20.66% YoY), while the FY2025 annual figure was $72.3 million, down 21.71% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $69.9 million, down from $72.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $112.5 million in Q4 2023, with the low at $45.0 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $95.3 million (2024), against an average of $90.1 million.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 163.56% in 2022, then retreated 28.98% in 2025.
• Zentalis Pharmaceuticals' Total Non-Current Liabilities stood at $102.7 million in 2022, then rose by 9.6% to $112.5 million in 2023, then dropped by 17.97% to $92.3 million in 2024, then declined by 21.71% to $72.3 million in 2025, then declined by 3.29% to $69.9 million in 2026.
• Business Quant data shows ZNTL's Total Non-Current Liabilities at $69.9 million in Q1 2026, $72.3 million in Q4 2025, and $73.9 million in Q3 2025.